ZMYND12

Across TCGA pan-cancer cohorts, ZMYND12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZMYND12 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZMYND12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZMYND12 expression acts as an unfavorable survival marker.

BLCA, LUSC, and PRAD are the cancer types where ZMYND12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
LUSC	OS	Median	All	0.120	0.776	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZMYND12–BLCA (OS)

Open the BLCA breakdown →